Finance
Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target
Pfizer's CEO Albert Bourla recently highlighted the company's "very big balance sheet" and its readiness to pursue transformative acquisitions despite heavy
Key takeaways
- Pfizer has a very big balance sheet to pursue potentially transformative acquisitions.
- Pfizer's lung cancer drug sigvotatug vedotin failed to meet its primary endpoint in a phase 3 study.
- Kailera Therapeutics would be an attractive acquisition target for Pfizer to expand its weight loss portfolio.
- Kailera Therapeutics' current market cap is $2.7 billion.
Pfizer's CEO Albert Bourla recently highlighted the company's "very big balance sheet" and its readiness to pursue transformative acquisitions despite heavy spending on past buyouts. This comes as Pfizer seeks to rebound from declining COVID-19 vaccine revenues and a recent clinical setback where its lung cancer drug, sigvotatug vedotin, failed to meet its primary endpoint in a phase 3 study. Analysts suggest Kailera Therapeutics, valued at $2.7 billion with its promising weight loss candidate ribupatide, could be an attractive acquisition target to bolster Pfizer's anti-obesity pipeline.
By the numbers
- $10B
- Maximum acquisition cost of Metsera including milestone payments
- $2.7B
- Current market capitalization of Kailera Therapeutics
- 7.1%
- Forward dividend yield offered by Pfizer
Want this on autopilot?
We file the Finance news, make the video, and post it for you.
Common questions
- marketing.blog.post.faq.what_happened
- Pfizer has a very big balance sheet to pursue potentially transformative acquisitions.
- marketing.blog.post.faq.source
- marketing.blog.post.faq.source_answer
